A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
Scartozzi, M;
2022-01-01
Abstract
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
atezovslenvaESMOOpen2022.pdf
accesso aperto
Tipologia:
versione post-print (AAM)
Dimensione
597.85 kB
Formato
Adobe PDF
|
597.85 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
